PDA1
MCID: PTN014
MIFTS: 59

Patent Ductus Arteriosus 1 (PDA1)

Categories: Blood diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Patent Ductus Arteriosus 1

MalaCards integrated aliases for Patent Ductus Arteriosus 1:

Name: Patent Ductus Arteriosus 1 57
Patent Ductus Arteriosus 57 11 19 75 5 14 63 31
Pda1 57 19 28 5
Ductus Arteriosus, Patent 11 43
Pda 57 19
Patent Ductus Arteriosus, Susceptibility to 57
Patent Ductus Arteriosus - Persisting Type 71
Patent Ductus Arteriosus Familial 19
Patency of the Ductus Arteriosus 19
Ductus Arteriosus Patent 53
Patent Ductus Botalli 11

Characteristics:


Inheritance:

Autosomal recessive 57

Classifications:



External Ids:

Disease Ontology 11 DOID:13832
OMIM® 57 607411
OMIM Phenotypic Series 57 PS607411
ICD9CM 34 747.0
MeSH 43 D004374
NCIt 49 C84492
SNOMED-CT 68 156928009
ICD10 31 Q25.0
MedGen 40 C4282128
SNOMED-CT via HPO 69 83330001
UMLS 71 C0013274 C3495549

Summaries for Patent Ductus Arteriosus 1

OMIM®: 57 Persistent patency of the ductus arteriosus, or patent ductus arteriosus (PDA), is the second most common congenital heart disease, affecting approximately 1 in 1,600 to 5,000 live births in the U.S. (Mitchell et al., 1971). In fetal life, the ductus arteriosus, a muscular artery, shunts blood from the pulmonary artery to the aorta, bypassing the lungs. Its abrupt closure at birth establishes the mature circulatory pattern and represents a dramatic example of vascular remodeling. Failure of this normal process results in persistent PDA, which left untreated can result in pulmonary hypertension and heart failure. Closure of the ductus is a complex process. Aspects of this process are regulated by oxygen tension and a decrease in levels of hormones such as prostaglandin E2. PDA occurring in preterm infants often closes spontaneously or in response to inhibitors of prostaglandin biosynthesis (Ramsay et al., 1987). Term PDA typically has not been regarded as a genetic disorder, because it most often occurs sporadically. Nonetheless, term PDA recurs among 5% of sibs of PDA cases (Polani and Campbell, 1960; Lamy et al., 1957), suggesting a genetic component to disease pathogenesis that has typically been presumed to be multifactorial. That single genes can influence this trait has been demonstrated by a mouse model of PDA resulting from disruption of the prostaglandin E2 receptor (Nguyen et al., 1997) and by rare syndromic forms of PDA such as Char syndrome (169100), an autosomal dominant disorder caused by mutations in the transcription factor TFAP2B (601601) (Mani et al., 2002). (607411) (Updated 08-Dec-2022)

MalaCards based summary: Patent Ductus Arteriosus 1, also known as patent ductus arteriosus, is related to aortic aneurysm, familial thoracic 4 and subvalvular aortic stenosis. An important gene associated with Patent Ductus Arteriosus 1 is FLNA (Filamin A), and among its related pathways/superpathways are Cardiac conduction and Human Embryonic Stem Cell Pluripotency. The drugs Poractant alfa and Beractant have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and brain, and related phenotypes are patent ductus arteriosus and homeostasis/metabolism

PubMed Health : 63 Patent ductus arteriosus: Patent ductus arteriosus (PDA) is a heart problem that affects some babies soon after birth. In PDA, abnormal blood flow occurs between two of the major arteries connected to the heart. These arteries are the aorta and the pulmonary (PULL-mun-ary) artery. Before birth, these arteries are connected by a blood vessel called the ductus arteriosus. This blood vessel is a vital part of fetal blood circulation. Within minutes or up to a few days after birth, the ductus arteriosus closes. This change is normal in newborns. In some babies, however, the ductus arteriosus remains open (patent). The opening allows oxygen-rich blood from the aorta to mix with oxygen-poor blood from the pulmonary artery. This can strain the heart and increase blood pressure in the lung arteries.

Wikipedia: 75 Patent ductus arteriosus (PDA) is a medical condition in which the ductus arteriosus fails to close... more...

Related Diseases for Patent Ductus Arteriosus 1

Diseases in the Patent Ductus Arteriosus 1 family:

Patent Ductus Arteriosus 2 Patent Ductus Arteriosus 3

Diseases related to Patent Ductus Arteriosus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 680)
# Related Disease Score Top Affiliating Genes
1 aortic aneurysm, familial thoracic 4 33.3 MYH11 FLNA FBN1 ACTA2
2 subvalvular aortic stenosis 32.8 TBX20 NKX2-5
3 holt-oram syndrome 32.8 TBX5 TBX20 PRODH NKX2-5 GATA4
4 periventricular nodular heterotopia 1 32.7 LOC107988032 FLNA
5 congenital heart defects, multiple types, 4 32.6 GATA4 CRELD1
6 char syndrome 32.4 TFAP2B TBX5 TBX20 MYH11 CRELD1
7 familial patent arterial duct 32.2 TFAP2B PRDM6
8 tetralogy of fallot 31.9 TFAP2B TBX5 TBX20 PTPN11 PRODH NPPB
9 aortic aneurysm 31.9 MYH11 FBN1 CRP ACTA2
10 patent foramen ovale 31.8 TBX5 TBX20 PTPN11 NPPB NKX2-5 LOC107988032
11 aortic dissection 31.8 MYH11 FBN1 CRP ACTA2
12 tricuspid valve insufficiency 31.8 PTPN11 NPPB MYH11 FBN1 CRP
13 aortic valve disease 1 31.6 TBX5 TBX20 NPPB NKX2-5 MYH11 GATA4
14 aortic aneurysm, familial thoracic 1 31.6 TFAP2B TBX5 TBX20 NKX2-5 MYH11 GATA4
15 atrioventricular septal defect 31.6 TBX5 TBX20 PRODH NKX2-5 GATA4 CRELD1
16 pulmonary valve stenosis 31.6 TBX5 PTPN11 NKX2-5 GATA4
17 total anomalous pulmonary venous return 1 31.6 TBX5 NKX2-5 GATA4 CRELD1
18 ebstein anomaly 31.6 TBX5 TBX20 NPPB NKX2-5 GATA4 FLNA
19 hypertrophic cardiomyopathy 31.4 TBX5 TBX20 PTPN11 NPPB NKX2-5 MYH11
20 cardiomyopathy, familial hypertrophic, 1 31.4 NKX2-5 MYH11 GATA4 ABCC9
21 diaphragmatic hernia, congenital 31.3 TBX5 GATA4 FBN1 CRP
22 lipoprotein quantitative trait locus 31.3 TBX5 TBX20 NPPB NKX2-5 MYH11 GATA4
23 pulmonary valve insufficiency 31.3 NPPB NKX2-5 FBN1 CRP
24 loeys-dietz syndrome 31.3 MYH11 FLNA FBN1 ACTA2
25 atrioventricular block 31.3 TBX5 NPPB NKX2-5 GATA4 CRP
26 right atrial isomerism 31.3 TBX5 TBX20 NKX2-5
27 orthostatic intolerance 31.2 TBX5 TBX20 NKX2-5 MYH11 FLNA FBN1
28 heart septal defect 31.2 TBX5 TBX20 PTPN11 PRODH NPPB NKX2-5
29 hemopericardium 31.2 NPPB FBN1 CRP
30 mitral valve disease 31.2 NPPB FLNA FBN1 CRP
31 pulmonary hypertension 31.1 NPPB NKX2-5 GATA4 CRP ACTA2
32 wolff-parkinson-white syndrome 31.1 TBX5 TBX20 NPPB NKX2-5 ABCC9
33 tricuspid atresia 31.1 TBX5 TBX20 PRODH NKX2-5 GATA4
34 third-degree atrioventricular block 31.1 TBX5 NPPB NKX2-5 CRP
35 orofaciodigital syndrome viii 31.1 TBX5 NKX2-5 GATA4
36 ventricular septal defect 31.1 TBX5 TBX20 PRODH NPPB NKX2-5 GATA4
37 aortic disease 31.1 NPPB MYH11 FBN1 CRP ACTA2
38 familial atrial fibrillation 31.1 TBX5 NKX2-5 GATA4 ABCC9
39 intestinal pseudo-obstruction 31.1 TFAP2B MYH11 FLNA
40 tracheal stenosis 30.9 TBX5 FLNA FBN1
41 noonan syndrome with multiple lentigines 30.9 TBX5 PTPN11 NKX2-5 GATA4
42 ehlers-danlos syndrome 30.9 MYH11 FLNA FBN1 ACTA2
43 megacystis-microcolon-intestinal hypoperistalsis syndrome 1 30.9 MYH11 FLNA ACTA2
44 spontaneous tension pneumothorax 30.9 NPPB CRP
45 heart valve disease 30.9 NPPB NKX2-5 FBN1 CRP
46 interatrial communication 30.9 TBX5 NKX2-5
47 atrial fibrillation 30.9 TBX5 NPPB CRP ABCC9
48 pectus excavatum 30.9 PTPN11 FBN1
49 noonan syndrome 1 30.9 TBX5 TBX20 PTPN11 NKX2-5 GATA4 FBN1
50 long qt syndrome 30.8 TBX5 NKX2-5 GATA4 ABCC9

Graphical network of the top 20 diseases related to Patent Ductus Arteriosus 1:



Diseases related to Patent Ductus Arteriosus 1

Symptoms & Phenotypes for Patent Ductus Arteriosus 1

Human phenotypes related to Patent Ductus Arteriosus 1:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 patent ductus arteriosus 30 HP:0001643

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Cardiovascular Vascular:
patent ductus arteriosus

Clinical features from OMIM®:

607411 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Patent Ductus Arteriosus 1:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 ABCC9 CRP FBN1 FLNA GATA4 INPP5E
2 nervous system MP:0003631 10.27 ABCC9 CRELD1 FBN1 FLNA GATA4 HYDIN
3 muscle MP:0005369 10.26 ABCC9 ACTA2 FBN1 GATA4 HYDIN MYH11
4 growth/size/body region MP:0005378 10.22 ABCC9 FBN1 FLNA GATA4 HYDIN INPP5E
5 cardiovascular system MP:0005385 10.09 ABCC9 ACTA2 CRELD1 CRP FBN1 FLNA
6 cellular MP:0005384 10.03 ABCC9 CRELD1 FBN1 FLNA GATA4 HYDIN
7 embryo MP:0005380 10.02 CRELD1 FBN1 GATA4 INPP5E NKX2-5 PRDM6
8 limbs/digits/tail MP:0005371 10 FBN1 GATA4 INPP5E PRODH PTPN11 TBX5
9 craniofacial MP:0005382 9.97 CRELD1 FBN1 FLNA HYDIN INPP5E NKX2-5
10 respiratory system MP:0005388 9.61 FBN1 FLNA GATA4 HYDIN MYH11 NKX2-5
11 mortality/aging MP:0010768 9.47 ABCC9 CRELD1 FBN1 FLNA GATA4 HYDIN

Drugs & Therapeutics for Patent Ductus Arteriosus 1

PubMed Health treatment related to Patent Ductus Arteriosus 1: 63

Patent ductus arteriosus (PDA) is treated with medicines, catheter -based procedures, and surgery . The goal of treatment is to close the PDA. Closure will help prevent complications and reverse the effects of increased blood volume. Small PDAs often close without treatment . For full-term infants, treatment is needed if the PDA is large or causing health problems. For premature infants, treatment is needed if the PDA is causing breathing problems or heart problems. Talk with your child's doctor about treatment options and how your family prefers to handle treatment decisions.

Drugs for Patent Ductus Arteriosus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Poractant alfa Approved Phase 4 129069-19-8
2
Beractant Approved Phase 4 108778-82-1
3 Pulmonary Surfactants Phase 4
4 Respiratory System Agents Phase 4
5
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
6
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
7
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
8
Dopamine Approved Phase 2, Phase 3 62-31-7, 51-61-6 681
9
Fenoldopam Approved Phase 2, Phase 3 67227-56-9, 67227-57-0 3341
10 Antipyretics Phase 2, Phase 3
11 Pharmaceutical Solutions Phase 2, Phase 3
12 Vasodilator Agents Phase 2, Phase 3
13 Neurotransmitter Agents Phase 2, Phase 3
14 Dopamine agonists Phase 2, Phase 3
15 Dopamine Agents Phase 2, Phase 3
16 Antihypertensive Agents Phase 2, Phase 3
17
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740
18
Lysine Approved, Nutraceutical Phase 2 56-87-1 5962
19
Meclocycline Investigational Phase 2 2013-58-3 54684337
20 Radiation-Protective Agents Phase 2
21 Phosphodiesterase Inhibitors Phase 2
22 Platelet Aggregation Inhibitors Phase 2
23 Antioxidants Phase 2
24 Protective Agents Phase 2
25 Vasoconstrictor Agents Phase 2
26
Iron Approved 7439-89-6 29936
27 Orange Approved
28
Adenosine Approved, Investigational 58-61-7 60961
29
Nitric Oxide Approved 10102-43-9 145068
30 Fibrin fragment D
31 Antifibrinolytic Agents
32 Hemostatics
33 Coagulants
34 Soy Bean
35 Omega 3 Fatty Acid
36 Analgesics, Opioid
37 Natriuretic Peptide, Brain
38 Liver Extracts
39 diuretics

Interventional clinical trials:

(show top 50) (show all 128)
# Name Status NCT ID Phase Drugs
1 Comparison Between the Effect of Oral Paracetamol Versus Oral Ibuprofen in the Treatment of Patent Ductus Arteriosus in Preterm and Low Birth Weight Infants Unknown status NCT03265782 Phase 4 ibuprofen;paracetamol
2 Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen Unknown status NCT01544972 Phase 4 Oral paracetamol;Oral ibuprofen
3 Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus Completed NCT00642330 Phase 4 oral ibuprofen;intravenous ibuprofen
4 Ibuprofen and Renal Function in Premature Infants Completed NCT00217191 Phase 4 Ibuprofen
5 Oral Paracetamol Versus Oral Ibuprofen Treatment Completed NCT01536158 Phase 4 Oral paracetamol;Oral ibuprofen
6 A Pilot, Randomized Controlled Study of the Effects of High Dose Ibuprofen on Cerebral and Splanchnic Tissue Oxygenation During Treatment of Hemodynamically Significant Patent Ductus Arteriosus (hsPDA) in Preterm Infants Not yet recruiting NCT05325177 Phase 4 Standard Dose Ibuprofen;High Dose Ibuprofen
7 Safety and Efficacy of an Optimized Ibuprofen Dosing Regimen Versus Standard Dosing for Pharmacologic Closure of Patent Ductus Arteriosus Terminated NCT00961753 Phase 4 optimized ibuprofen;Standard Ibuprofen
8 Phase 4 Study of Curosurf (Poractant) and Survanta (Beractant) Surfactant Treatment in Very Premature Infants With Respiratory Distress Syndrome. Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
9 A Randomised Controlled Trial Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus In Very Premature Infants Withdrawn NCT00470743 Phase 4 Ibuprofen;Indomethacin
10 Paracetamol Versus Ibuprofen in Premature Infants With Hemodynamically Significant Patent Ductus Arteriosus: a Randomized Clinical Trial Unknown status NCT04037514 Phase 3 Paracetamol;Ibuprofen
11 Alternative Acetaminophen Treatment of the Hemodynamivally Significant Patent Ductus Arteriosus in Preterm Neonates Who Are Not Candidates for Enteral Administration: A Pilot Study Unknown status NCT03604796 Phase 2, Phase 3 Rectal Solution;Intravenous Infusion
12 Phase III Clinical Trial, Randomized, Multicentre, Double Blind to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis Unknown status NCT04282941 Phase 3 Ibuprofen in continuous (24 hours) iv infusion and EchoG;IV bolus Ibuprofen slow (15 minutes) and EchoG
13 Randomized, Double-Blind Study of Ibuprofen L-Lysine Intravenous Solution in Premature Infants for the Early Treatment of Patent Ductus Arteriosus Completed NCT00440804 Phase 3 ibuprofen l-lysine iv solution (NeoProfen (R) )
14 Comparison of Intravenous Ibuprofen vs. Continuous Indomethacin in the Treatment of Patent Ductus Arteriosus Completed NCT00485160 Phase 3 Continuous indomethacin;ibuprofen
15 Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants: A Pilot, Double Blind, Randomized, Placebo-control Trial Completed NCT02002741 Phase 2, Phase 3 Paracetamol;Placebo
16 Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Open Label, Controlled Trial Completed NCT03022253 Phase 3 Paracetamol;Ibuprofen
17 Randomised Controlled Clinical Trial of Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus: a Pilot Study Completed NCT01593163 Phase 3 Ibuprofen EchoG;Standard ibuprofen treatment
18 Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI) Completed NCT01630278 Phase 3 Ibuprofen;Placebo
19 High-dose Ibuprofen for Patent Ductus Arteriosus in Extremely Preterm Infants: a Randomized Controlled Study Completed NCT01243996 Phase 2, Phase 3 Ibuprofen
20 Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP) Completed NCT00009646 Phase 3 indomethacin;Indomethacin;Placebo
21 Management of Patent Ductus in Premature Infants Completed NCT00000494 Phase 3 indomethacin
22 Management of the Patent Ductus Arteriosus in Premature Infants Trial (PDA Trial) Recruiting NCT03456336 Phase 3
23 Selective Early Medical Treatment of the Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot Randomized Controlled Trial Recruiting NCT05011149 Phase 3 Ibuprofen
24 PAIR (Paracetamol and Ibuprofen Research) Study: A Randomised Controlled Trial Comparing IV Paracetamol With IV Ibuprofen in the Management of Haemodynamically Significant Patent Ductus Arteriosus Recruiting NCT04986839 Phase 2, Phase 3 Paracetamol injection;Ibuprofen injection
25 Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen Recruiting NCT04459117 Phase 2, Phase 3 Acetaminophen;NACL 0.9%
26 Paracetamol Versus Ibuprofen for Patent Ductus Arteriosus Closure in Preterm Infants. A Prospective, Randomized, Controlled, Double Blind, Multicenter Clinical Trial. Suspended NCT02056223 Phase 2, Phase 3 Intravenous paracetamol;Intravenous ibuprofen
27 An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants- A Randomized Pilot Study Terminated NCT00750581 Phase 2, Phase 3 Indomethacin
28 Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Terminated NCT02620761 Phase 2, Phase 3 Fenoldopam;0.9%NS
29 Comparison of the Efficacy of IV Acetaminophen Versus IV Indomethacin in Treatment of Hemodynamically Significant PDA in VLBW Infants Terminated NCT03537144 Phase 3 Indomethacin;Acetaminophen
30 TIME TO RE-EVALUATE THE KINDER GENTLER APPROACH TO PATENT DUCTUS ARTERIOSUS (PDA) IN THE PRETERM NEONATE Unknown status NCT02819414 Phase 2 Paracetamol drops
31 Comparison of Oral and Intravenous Ibuprofen for Treatment of Patent Ductus Arteriosus in Extremely Premature Infants: A Randomized Controlled Trial Unknown status NCT01149564 Phase 1, Phase 2 iv ibuprofen;oral ibuprofen
32 New Therapeutic Approaches to the Resistant Patent Ductus Arteriosus (PDA) in Low Birth Weight Neonates Unknown status NCT00616382 Phase 2 Indomethacin;Pentoxifylline
33 Paracetamol in the Treatment of Patent Ductus Arteriosus in the Premature Neonate Unknown status NCT01291654 Phase 2 Paracetamol;NSAID;D5W
34 The Best Treatment Strategy: Surgical Versus Pharmacological, to Close the Ductus Arteriosus Persistent in Preterm Infants. A Randomized Controlled Trial Unknown status NCT02602054 Phase 2 Control group
35 Oral Ibuprofen Versus Placebo in Management of Patent Ductus Arteriosus in Preterm Infants: A Double Blind, Randomized Control Trial Completed NCT05493540 Phase 2 Ibuprofen oral suspension;Placebo
36 Efficacy and Safety of No Treatment Compared With Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants: a Randomized, Double-blind, Placebo-controlled, Non-inferiority Clinical Trial Completed NCT02128191 Phase 2 Oral ibuprofen;Normal saline
37 Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus in Preterm infants-a Multicenter Trial Completed NCT01958320 Phase 2 NSAID
38 Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus Completed NCT00187447 Phase 2 indomethacin (two different dosing regimens)
39 Efficacy and Safety of Paracetamol in Comparison to Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants: A Randomized, Open Label, Comparator-controlled, Prospective Study Completed NCT02422966 Phase 2 Paracetamol;Ibuprofen
40 The Preterm Infants' Paracetamol Study Recruiting NCT01938261 Phase 2 paracetamol;0.45 % saline solution
41 Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants - The ACEDUCT Trial Not yet recruiting NCT05340582 Phase 2 Acetaminophen Injection;Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)
42 Single Center, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus Terminated NCT03701074 Phase 2 Ibuprofen and acetaminophen;Ibuprofen and placebo
43 Monotherapy (Ibuprofen) vs. Combination Therapy (Ibuprofen and Acetaminophen) in the Management of Patent Ductus Arteriosus in Premature Infants: A Randomized Controlled Trial Withdrawn NCT04026464 Phase 2 Intravenous Ibuprofen;Intravenous Ibuprofen + Oral Acetaminophen
44 Ibuprofen vs. Indomethacin as Second Course of Therapy for Resistant PDA in Low Birth Weight Neonates Withdrawn NCT01070745 Phase 2 Indomethacin;Ibuprofen
45 Pharmacokinetics and Pharmacodynamics of Indomethacin Used for PDA Treatment in Extremely Preterm Neonates <27 Weeks Gestational Age Withdrawn NCT04025177 Phase 2 Indomethacin Injection
46 Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus in Premature Infants: A Pilot Study Completed NCT03103022 Phase 1 Acetaminophen;ibuprofen
47 Phase 1 Study for Safety and Effectiveness of the New Occlutech PDA Occluder, for Non Surgical Closure of Patent Ductus Arteriosus Completed NCT01479218 Phase 1
48 Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus of Preterm Infants - Randomised, Placebo-controlled Multicentre Trial Recruiting NCT03648437 Phase 1 Paracetamol 10Mg/mL;0.45% Sodium Chloride;Ibuprofen;Indomethacin
49 Chest Shielding for Prevention of a Patent Ductus Arteriosus in Preterm Infants Receiving Phototherapy Effect of Phototherapy Unknown status NCT03675425
50 Timing of Closure of Patent Foramen Ovale and Patent Ductus Arteriosus Following Birth Unknown status NCT01032785

Search NIH Clinical Center for Patent Ductus Arteriosus 1

Cochrane evidence based reviews: ductus arteriosus, patent

Genetic Tests for Patent Ductus Arteriosus 1

Genetic tests related to Patent Ductus Arteriosus 1:

# Genetic test Affiliating Genes
1 Pda1 28

Anatomical Context for Patent Ductus Arteriosus 1

Organs/tissues related to Patent Ductus Arteriosus 1:

MalaCards : Heart, Lung, Brain, Liver, Smooth Muscle, Kidney, Thyroid

Publications for Patent Ductus Arteriosus 1

Articles related to Patent Ductus Arteriosus 1:

(show top 50) (show all 9439)
# Title Authors PMID Year
1
Genetics of patent ductus arteriosus susceptibility and treatment. 62 57
22414880 2012
2
Finding genetic contributions to sporadic disease: a recessive locus at 12q24 commonly contributes to patent ductus arteriosus. 62 57
12409608 2002
3
Response of the patent ductus arteriosus to indomethacin treatment. 62 57
3812411 1987
4
A Screening Approach to Identify Clinically Actionable Variants Causing Congenital Heart Disease in Exome Data. 5
29555671 2018
5
The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. 57
9363893 1997
6
Congenital heart disease in 56,109 births. Incidence and natural history. 57
5102136 1971
7
Factors in the causation of persistent ductus arteriosus. 57
13736684 1960
8
Genetic and non-genetic factors in the etiology of congenital heart disease: a study of 1188 cases. 57
13410899 1957
9
B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. 53 62
18981033 2009
10
Longitudinal changes of brain-type natriuretic peptide in preterm neonates. 53 62
16740863 2006
11
Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. 53 62
16222347 2005
12
The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. 53 62
16027692 2005
13
Trial of paracetamol for premature newborns: five-year follow-up. 62
33478294 2022
14
Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. 62
36008521 2022
15
Effects of prophylactic indomethacin on morbidity and mortality in infants <25 weeks' gestation: a protocol driven intention to treat analysis. 62
36310242 2022
16
The Possible Protective Role of Bilirubin on Oxidative Stress Related Morbidity in Preterm Infants. 62
34821525 2022
17
Laryngeal reinnervation for paediatric vocal cord palsy: a systematic review. 62
35838782 2022
18
Effects of less invasive surfactant administration versus intubation-surfactant-extubation on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: a single-center, retrospective study from China. 62
36471386 2022
19
A comparison of the effect of bi-level positive airway pressure and synchronized intermittent mandatory ventilation in preterm infants with respiratory distress syndrome. 62
33573450 2022
20
A rare association of Down syndrome with Dandy -Walker variant, pulmonary hypertension and childhood interstitial lung disease: A case report of a prognostic dilemma. 62
36212578 2022
21
Eisenmenger Syndrome Among Children with Unrepaired Congenital Heart Defects in Yunnan, China. 62
35522268 2022
22
Combined (dual) drug therapy for the treatment of patent ductus arteriosus: last approach prior to ligation. 62
36472120 2022
23
Patent ductus arteriosus and spontaneous intestinal perforation in a cohort of preterm infants. 62
35589970 2022
24
Descending aorta flow pattern in a neonate with patent ductus arteriosus coexisting with liver hemangioma. 62
33837505 2022
25
Correction to: Costs associated with acute kidney injury in critically Ill neonates with patent Ductus arteriosus: pediatric health information system (PHIS) analysis. 62
36329163 2022
26
Comment on "Fluid restriction in management of patent ductus arteriosus in Italy: a nationwide survey". 62
36454298 2022
27
A Better Way for Ductal Stenting in Patients with Duct-Dependent Pulmonary Flow and Vertical and Tortuous Patent Ductus Arteriosus. 62
35949124 2022
28
Costs associated with acute kidney injury in critically Ill neonates with patent Ductus arteriosus: pediatric health information system (PHIS) analysis. 62
36071104 2022
29
The chance of spontaneous patent ductus arteriosus closure in preterm infants born before 32 weeks of gestation is high and continues to increase until 5 years of follow-up. 62
36098710 2022
30
The "Hand as Foot" teaching method in patent ductus arteriosus. 62
35768301 2022
31
The effect of patent ductus arteriosus treatment with paracetamol on pulmonary vascular resistance. 62
35585179 2022
32
The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants. 62
35840707 2022
33
Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital. 62
33980104 2022
34
Neutrophil gelatinase-associated lipocalin distribution in preterm newborns without acute kidney injury as defined by a reference method. 62
33455508 2022
35
Utility of Follow-Up Echocardiograms in Uncomplicated PDA Device Closures Performed During Infancy. 62
36074260 2022
36
Low flow nasal cannula requirement among preterm infants: predictors and description of clinical course. 62
36045221 2022
37
Institutional Trend in Device Selection for Transcatheter PDA Closure in Premature Infants. 62
35430709 2022
38
Bedside Cerebral Blood Flow Quantification in Neonates. 62
36182604 2022
39
Exploring Noncardiac Surgical Needs From Infancy to Adulthood in Patients With Congenital Heart Disease. 62
36216687 2022
40
Intraventricular hemorrhage prediction in premature neonates in the era of hemodynamics monitoring: a prospective cohort study. 62
36171508 2022
41
Iatrogenic left common carotid artery to right internal jugular vein arteriovenous fistula closure. 62
36248379 2022
42
Anastomosis near to the ileocecal valve in neonates with focal intestinal perforation, is it safe. 62
34096446 2022
43
Respiratory problems in preterm infants with pulmonary hemorrhage. 62
34384331 2022
44
Maldevelopment of the Immature Pulmonary Vasculature and Prolonged Patency of the Ductus Arteriosus - Association or Cause? 62
36470238 2022
45
Analysis of risk factors related to extremely and very preterm birth: a retrospective study. 62
36335328 2022
46
[Influence of hypotension on the short-term prognosis of preterm infants with a gestational age of <32 weeks]. 62
36398543 2022
47
Circumflex aortic arch: presentation across various age groups: a case series. 62
36258834 2022
48
Bedside tracking of functional autonomic age in preterm infants. 62
36376508 2022
49
Comparison of neonatal morbidity and mortality between single-room and open-bay care: a retrospective cohort study. 62
35444004 2022
50
Contributions of the NICHD neonatal research network to the diagnosis, prevention, and treatment of bronchopulmonary dysplasia. 62
36085059 2022

Variations for Patent Ductus Arteriosus 1

ClinVar genetic disease variations for Patent Ductus Arteriosus 1:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LOC107988032, FLNA NM_001110556.2(FLNA):c.7671del (p.Ser2558fs) DEL Pathogenic
1341468 GRCh37: X:153577815-153577815
GRCh38: X:154349447-154349447
2 INPP5E NM_019892.6(INPP5E):c.1132C>T (p.Arg378Cys) SNV Pathogenic
400 rs121918130 GRCh37: 9:139327634-139327634
GRCh38: 9:136433182-136433182
3 PTPN11 NM_002834.5(PTPN11):c.184T>G (p.Tyr62Asp) SNV Pathogenic
13329 rs121918460 GRCh37: 12:112888168-112888168
GRCh38: 12:112450364-112450364
4 ABCC9 NM_020297.4(ABCC9):c.3460C>T (p.Arg1154Trp) SNV Pathogenic
31946 rs387907208 GRCh37: 12:21995261-21995261
GRCh38: 12:21842327-21842327
5 FLNA NM_001110556.2(FLNA):c.2761C>T (p.Arg921Ter) SNV Likely Pathogenic
93752 rs398123614 GRCh37: X:153590412-153590412
GRCh38: X:154362044-154362044
6 HYDIN NM_001270974.2(HYDIN):c.10816G>T (p.Gly3606Ter) SNV Likely Pathogenic
598961 rs1567744830 GRCh37: 16:70908340-70908340
GRCh38: 16:70874437-70874437
7 BMP2 NM_001200.4(BMP2):c.721A>T (p.Lys241Ter) SNV Uncertain Significance
1703209 GRCh37: 20:6759266-6759266
GRCh38: 20:6778619-6778619
8 VANGL1 NM_138959.3(VANGL1):c.523C>T (p.Arg175Trp) SNV Uncertain Significance
167818 rs142594314 GRCh37: 1:116206600-116206600
GRCh38: 1:115663979-115663979
9 TNFRSF13B NM_012452.3(TNFRSF13B):c.310T>C (p.Cys104Arg) SNV Uncertain Significance
5302 rs34557412 GRCh37: 17:16852187-16852187
GRCh38: 17:16948873-16948873
10 HYDIN NM_001270974.2(HYDIN):c.6631G>A (p.Asp2211Asn) SNV Uncertain Significance
598962 rs748644598 GRCh37: 16:70977753-70977753
GRCh38: 16:70943850-70943850

Expression for Patent Ductus Arteriosus 1

Search GEO for disease gene expression data for Patent Ductus Arteriosus 1.

Pathways for Patent Ductus Arteriosus 1

GO Terms for Patent Ductus Arteriosus 1

Biological processes related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 10.03 TBX5 PTPN11 NKX2-5 GATA4 FBN1
2 heart looping GO:0001947 10.01 TBX20 NKX2-5 GATA4
3 aortic valve morphogenesis GO:0003180 9.88 GATA4 NKX2-5 TBX20
4 forelimb morphogenesis GO:0035136 9.83 TFAP2B TBX5
5 atrioventricular node development GO:0003162 9.8 NKX2-5 GATA4
6 atrioventricular node cell development GO:0060928 9.78 TBX5 NKX2-5
7 bundle of His development GO:0003166 9.76 TBX5 NKX2-5
8 atrioventricular canal development GO:0036302 9.73 TBX20 PTPN11 GATA4
9 cardiac ventricle morphogenesis GO:0003208 9.69 NKX2-5 GATA4
10 cardiac muscle cell differentiation GO:0055007 9.67 TBX5 NKX2-5 GATA4
11 endocardial cushion development GO:0003197 9.63 TBX5 GATA4 CRELD1
12 atrioventricular node cell fate commitment GO:0060929 9.62 TBX5 NKX2-5
13 positive regulation of cardioblast differentiation GO:0051891 9.43 TBX5 NKX2-5 GATA4
14 atrial septum morphogenesis GO:0060413 9.23 TBX5 TBX20 NKX2-5 GATA4

Molecular functions related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II-specific DNA-binding transcription factor binding GO:0061629 9.23 TBX5 TBX20 NKX2-5 GATA4

Sources for Patent Ductus Arteriosus 1

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....